Renal Cancer
MicroRNA-155-5p targets NR3C2 to promote malignant progression of clear cell renal cell carcinoma.
January 28, 2022
Prediction of early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitor.
January 28, 2022
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
January 27, 2022
Pyroptosis Regulators and Tumor Microenvironment Infiltration Characterization in Clear Cell Renal Cell Carcinoma.
January 27, 2022
Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists.
January 27, 2022
Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment.
January 26, 2022
Identification of prognostic biomarkers in papillary renal cell carcinoma and PTTG1 may serve as a biomarker for predicting immunotherapy response.
January 25, 2022
The effect of frailty on post-operative outcomes and health care expenditures in patients treated with partial nephrectomy.
January 24, 2022
IL-1A is associated with postoperative survival and immune contexture in clear cell renal cell carcinoma.
January 21, 2022
A Bioinformatic Analysis of Immune-Related Prognostic Genes in Clear Cell Renal Cell Carcinoma Based on TCGA and GEO Databases.
January 20, 2022
Risk of recurrence after nephrectomy: Comparison of predictive ability of validated risk models.
January 19, 2022
Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review.
January 19, 2022
Risk-group Classification by Recursive Partitioning Analysis of Patients Affected by Oligometastatic Renal Cancer Treated with Stereotactic Radiotherapy.
January 18, 2022